Barinthus Biotherapeutics (BRNS) AI Stock Analysis

• Market Cap: $44.38M
• Dividend Yield: N/A
• Average Volume (3M): 40.58K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.63
• Revenue Growth: N/A
• EPS Growth: -5.42%
• Country: US
• Employees: 105
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.52
• Shares Outstanding: 40,718,227
• 10 Day Avg. Volume: 58,329
• 30 Day Avg. Volume: 40,577
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.86
• Enterprise Value/Revenue: -2.55
• Enterprise Value/Gross Profit: 32.66
• Enterprise Value/Ebitda: 0.61
• 1Y Price Target: $3.00
• Price Target Upside: 172.73% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 46 Neutral
• Price Target: $1.00 ▼(-9.09% Downside)

Barinthus Biotherapeutics faces significant financial challenges with ongoing losses and cash flow issues, which are the most impactful factors on its stock score. The technical analysis indicates a bearish trend, and the valuation is unattractive due to the negative P/E ratio. These factors combined result in a low overall stock score.

Positive Factors

Business Model Strength

A diversified revenue model through sales, licensing, and partnerships provides resilience and multiple income streams, supporting long-term growth.

Balance Sheet Stability

A strong equity position with manageable leverage enhances financial stability, providing a solid foundation for future investments and growth.

Improved Gross Profit Margins

Improved gross profit margins suggest effective cost management, which can lead to better profitability and competitive pricing in the long term.

Negative Factors

Ongoing Losses

Persistent losses indicate challenges in achieving profitability, which can impact long-term financial health and limit reinvestment opportunities.

Cash Flow Issues

Negative cash flows suggest liquidity constraints, which may hinder the company's ability to fund operations and invest in growth initiatives.

Unprofitability

Continued unprofitability poses a risk to financial sustainability, potentially affecting investor confidence and access to capital markets.

Barinthus Biotherapeutics Business Overview & Revenue Model

Company Description

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

How the Company Makes Money

Barinthus Biotherapeutics generates revenue through a multifaceted business model that includes product sales, licensing agreements, and strategic partnerships. The company earns income from the commercialization of its proprietary therapies, which are sold to healthcare providers and institutions. Additionally, Barinthus licenses its technologies and drug candidates to other pharmaceutical companies, earning royalty payments and milestone fees. The company also engages in collaborative research and development partnerships, which provide funding and shared revenue opportunities. These collaborations often include co-development and co-marketing agreements that further enhance Barinthus's financial position.

Barinthus Biotherapeutics Financial Statement Overview

Summary

Barinthus Biotherapeutics is experiencing financial challenges with ongoing losses and cash flow issues, despite improvements in revenue and gross profit margins. The balance sheet is stable, but the company needs to focus on achieving profitability and improving cash flow.

Income Statement

Barinthus Biotherapeutics has shown significant volatility in its revenue and profitability. The revenue growth from 2023 to 2024 was substantial, but the company remains unprofitable with negative net income and EBIT margins. The gross profit margin improved in 2024, indicating better cost management, but the overall financial health is hindered by persistent losses.

Balance Sheet

The company's balance sheet reflects a strong equity position with a high equity ratio, indicating stability. However, the debt-to-equity ratio is relatively low, suggesting manageable leverage. The decline in stockholders' equity over the years is a concern, but the reduction in total liabilities is a positive sign.

Cash Flow

Cash flow analysis reveals challenges with negative operating and free cash flows, indicating potential liquidity issues. The free cash flow has improved slightly from 2023 to 2024, but the company continues to burn cash, which could be a risk if not addressed.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.97M	14.97M	802.00K	44.70M	268.00K	4.82M
Gross Profit	-1.17M	14.97M	-4.64M	44.70M	268.00K	4.82M
EBITDA	-62.56M	-55.37M	-71.06M	6.40M	-47.87M	-14.03M
Net Income	-69.42M	-61.07M	-73.35M	5.34M	-50.87M	-17.71M
Balance Sheet
Total Assets	129.56M	160.33M	214.51M	270.20M	280.71M	50.67M
Cash, Cash Equivalents and Short-Term Investments	86.26M	110.66M	142.09M	194.38M	214.05M	43.27M
Total Debt	11.99M	12.01M	12.98M	8.77M	7.22M	46.36M
Total Liabilities	27.08M	30.19M	27.51M	27.00M	28.15M	87.58M
Stockholders Equity	102.38M	130.03M	186.78M	242.90M	252.13M	-37.30M
Cash Flow
Free Cash Flow	-38.54M	-29.83M	-56.34M	-20.57M	-33.73M	-11.32M
Operating Cash Flow	-38.12M	-28.94M	-50.92M	-14.43M	-32.58M	-11.03M
Investing Cash Flow	-429.22K	-892.00K	-5.41M	-5.75M	-12.91M	-293.00K
Financing Cash Flow	1.30M	2.16M	1.87M	325.00K	222.74M	41.44M

Barinthus Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRNS, the sentiment is Negative. The current price of 1.1 is below the 20-day moving average (MA) of 1.18, below the 50-day MA of 1.29, and above the 200-day MA of 1.04, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 42.82 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BRNS.

Barinthus Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.92B	-0.36	-43.38%	2.24%	22.38%	-2.16%
ALGS	47 Neutral	$62.74M	―	-87.74%	―	-60.16%	―
BRNS	46 Neutral	$44.38M	―	-53.78%	―	―	-5.42%
CLGN	44 Neutral	$33.32M	―	-78.25%	―	248.62%	26.22%
GDTC	41 Neutral	$26.64M	―	-24.97%	―	―	38.80%
BOLD	40 Underperform	$25.74M	―	-42.65%	―	―	-10.95%
ALXO	39 Underperform	$56.76M	―	-104.21%	―	―	39.60%

Barinthus Biotherapeutics Corporate Events

Barinthus Biotherapeutics Approves Key Proposals at AGM

On June 10, 2025, Barinthus Biotherapeutics held its Annual General Meeting where all proposed matters were approved, including the re-election of directors and the appointment of auditors. The meeting also covered financial matters such as the approval of the directors’ remuneration policy and the decision not to pay dividends for the fiscal year ending December 31, 2024.